ClinicalTrials.gg
CompletedNCT07167069Updated Sep 29, 2026

India HIV-CervCa Project

An observational study in HIV Positive, HIV Negative and Cervical Cancer, sponsored by Abramson Cancer Center at Penn Medicine. Completed at 1 site in India. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Abramson Cancer Center at Penn Medicine · Observational

How we know

Updated Sep 29, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
180
Ages
18 Years and older
Sex
Female
01

Study summary

The investigators propose to prospectively study the difference in treatment (CTRT) completion and toxicities between HIV positive and HIV negative women in India with locally advanced cervical cancer receiving CTRT.

Read the detailed description

This study will compare chemoradiation completion rates for cervical cancer in two groups, women with HIV and women without HIV. The investigators will also be analyzing tumor tissue for tumor infiltrating lymphocytes which are thought to be involved in disease progression.

02

Conditions studied

  • HIV Positive
  • HIV Negative
  • Cervical Cancer

Keywords

  • Chemotherapy
  • Concurrent Chemoradiotherapy
  • Radiotherapy
03

In context

HIV Seropositivity

194 studies on the registry are indexed under HIV Seropositivity; 10 are open to participants now.

This study's enrollment of 180 is below the median of 251 across 74 observational studies indexed under HIV Seropositivity.

Browse HIV Seropositivity studies →

Lead sponsor

Abramson Cancer Center at Penn Medicine is the lead sponsor of 462 studies on the registry; 88 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 14 (42%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with cervical cancer at Tata Memorial Hospital in India.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with newly proven squamous carcinoma or adenocarcinoma of the uterine cervix, FIGO stage IB2-IIIB in whom curative CTRT is planned
  • performance status ≥ 70
  • Patients with lower paraortic lymph nodes (below the level of L2 vertebra)
  • patients diagnosed with cervical cancer whom also positive or HIV negative

Exclusion criteria

Exclusion Criteria:

  • patients with active tuberculosis
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
180 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • HIV Positive

    Cervical Cancer Patients with HIV positive

    Radiation: Radiation Therapy

  • HIV Negative

    Cervical Cancer Patients with HIV negative

    Radiation: Radiation Therapy

Interventions

  • RadiationRadiation Therapy

    Standard of Care Chemoradiation for Cervical cancer patients in India.

06

What researchers measure

Primary outcomes

  1. Completion Rates of Cancer Treatment

    To evaluate and compare the completion rates of cancer treatment in HIV positive cervical cancer patients and HIV negative cervical cancer patients. Treatment adherence is defined as receiving at least 5 cycles of weekly cisplatin chemotherapy and completion of all prescribed radiation (including brachytherapy) and chemotherapy within 8 weeks of treatment initiation.

    Time frame: 2 years

  2. Impact of HIV Infection on acute toxicities

    To compare the incidence of acute grade ≥3 gastrointestinal, genitourinary and hematological toxicities using CTCAE v4 in patients receiving concurrent cisplatin-based chemo-radiation and brachytherapy for cervical cancer in HIV positive and HIV negative patients. Acute toxicities include any toxicity occurring within 90 days of treatment completion.

    Time frame: 2 years

Secondary outcomes

  1. Tumor infiltrating lymphocytes (TILs)

    To identify and characterize tumor infiltrating lymphocytes (TILs) with reference to numbers and phenotype in tumor biopsies of HIV positive and HIV negative cervical cancer patients in India

    Time frame: 2 Years

07

Study locations

1 site
  • Tata Memorial Hospital
    Mumbai, Maharashtra 400012, India
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Sep 2026, 66 months.

Of 24 observational studies under HIV Seropositivity, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 130. This study's 66 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: primary completion May 2026 → Sep 2026 and completion May 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2025
First posted
Sep 11, 2025
StartActual
Feb 9, 2021
Primary completionActual
Sep 1, 2026was May 2026
CompletionActual
Sep 1, 2026was May 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Sep 29, 2026
Primary completion
May 2026→Sep 1, 2026 (actual)
Sep 29, 2026
Study completion
May 2026→Sep 1, 2026 (actual)
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Active, not recruiting→Completed
    Primary completion May 2026→Sep 1, 2026 (now actual)
    Study completion May 2026→Sep 1, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07167069
Responsible party
Sponsor
First posted
Sep 11, 2025
Start date
Feb 9, 2021
Primary completion
Sep 1, 2026
Completion
Sep 1, 2026
Last update
Sep 29, 2026

Study contacts

Surbhi Grover, MD, MPH
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion